Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.
Newer drug combinations help more patients with Ph-positive ALL avoid immediate stem cell transplants after achieving remission.
This PubMed record reports a randomized controlled trial about Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. The available abstract indicates As of this report, only 19% of the patients in the intervention group had undergone hematopoietic stem-cell transplantation after having had a first complete hematologic response.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants
- Sample size
- 236
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- The New England journal of medicine
Why it surfaced
Randomized controlled trial; directly matches Hematologic malignancies, Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Conservative abstract-level score 9/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.